Best of ASCO 2023 Annual Meeting
  1. Página Inicial

Programação

Filtrar atividades
Plenária
09:30 - 10:45 Módulo

Módulo Mama

09:30 - 09:35
Abstract 1006
An age-specific pooled analysis of trastuzumab deruxtecan (T DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.
09:35 - 09:40
Abstract 1007
Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.
09:40 - 09:45
Abstract 1003
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).
09:45 - 09:52
LBA 500
Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.
09:52 - 10:00
Abstract 501
Efficacy and safety results by age in monarche: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
10:00 - 10:07
LBA 1000
Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
10:07 - 10:15
Abstract 503
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.
10:15 - 10:45
Discussão
Plenária
10:45 - 11:15 Intervalo

Intervalo

Plenária
11:15 - 11:45 Simpósio Satélite

Simpósio Satélite - Impacto do tratamento adjuvante com inibidores de CDK 4/6 em câncer de mama HR positivo HER2 negativo: novas perspectivas com resultados do estudo NATALEE